1. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A
- Author
-
Chen, Mingming, Asanuma, Miwako, Takahashi, Mari, Shichino, Yuichi, Mito, Mari, Fujiwara, Koichi, Saito, Hironori, Floor, Stephen N, Ingolia, Nicholas T, Sodeoka, Mikiko, Dodo, Kosuke, Ito, Takuhiro, and Iwasaki, Shintaro
- Subjects
Male ,ribosome profiling ,Cultured ,Cells ,dominant negative ,Molecular Conformation ,translation inhibitor ,Molecular ,translation ,RNA Bind-n-Seq ,DEAD-box RNA Helicases ,ribosome ,Models ,DDX3 ,rocaglate ,Eukaryotic Initiation Factor-4A ,Genetics ,Humans ,RNA ,Female ,eIF4A ,Enzyme Inhibitors ,Benzofurans ,Cancer - Abstract
The translation inhibitor rocaglamide A (RocA) has shown promising antitumor activity because it uniquely clamps eukaryotic initiation factor (eIF) 4A onto polypurine RNA for selective translational repression. As eIF4A has been speculated to be a unique target of RocA, alternative targets have not been investigated. Here, we reveal that DDX3 is another molecular target of RocA. Proximity-specific fluorescence labeling of an O-nitrobenzoxadiazole-conjugated derivative revealed that RocA binds to DDX3. RocA clamps the DDX3 protein onto polypurine RNA in an ATP-independent manner. Analysis of a de novo-assembled transcriptome from the plant Aglaia, a natural source of RocA, uncovered the amino acid critical for RocA binding. Moreover, ribosome profiling showed that because of the dominant-negative effect of RocA, high expression of eIF4A and DDX3 strengthens translational repression in cancer cells. This study indicates that sequence-selective clamping of DDX3 and eIF4A, and subsequent dominant-negative translational repression by RocA determine its tumor toxicity.
- Published
- 2021